Within the RA subjects, ten patients were currently using nonbiological DMARDs, after they successfully discontinued their anti-TNF therapy for more than 6 months, whereas 13 patients used anti-TNF therapy. The gene discussed is TNF; the disease is rheumatoid arthritis.